Rene A. Braeckman, Ph.D.

Dr. Braeckman has served as Zevra Therapeutics (then KemPharm, Inc.) vice president, clinical development since April 2016. Prior to joining Zevra, Dr. Braeckman was vice president of clinical development for Amarin Pharma, Inc. where he led multiple successful IND and NDA filings and managed the strategic planning and design of two pivotal Phase 3 clinical trials.

Prior to Amarin, Dr. Braeckman was chief scientific officer and senior VP of operations for Reliance Clinical Research Services (RCRS), the U.S. subsidiary of Reliance Life Sciences. Additional career accomplishments include executive and senior level positions with Valeant Pharmaceuticals International, RABpharma LLC, Pan Pacific Pharmaceuticals, Ceptyr, Inc., Chiron Corporation and Abbott Laboratories.

Dr. Braeckman has more than 30 years of experience in drug development, and is the co-author of more than 50 publications and co-inventor on more than 20 patents.

He earned his doctorate in clinical pharmacology/pharmacokinetics from the University of Gent in Belgium.